Stevanato Group (STVN) investor relations material

Company overview and strategic direction

• Founded in 1949, the company has evolved to focus on the pharmaceutical industry, especially in Europe, the US, and Asia, with a sophisticated value proposition for mission-critical glass products.

• The company produces billions of ready-to-fill syringes, vials, and cartridges annually across 13 sites in 9 countries, emphasizing quality and technological partnership.

• Proprietary product platforms now include drug delivery devices like auto-injectors and pens, alongside glass products, with selective contract manufacturing.

• Internal engineering capabilities have created a competitive advantage, enabling end-to-end integrated offerings and global leadership in vials and cartridges.

• The company serves over 23 top global customers and has a portfolio of 700 customers worldwide.

Growth, investments, and financial outlook

• Revenue has grown from €20 million to a guided €1.3 billion by the end of 2026, driven by organic growth and R&D investment.

• $1.2 billion was raised through IPO and offerings, with 70% reinvested to expand capacity, especially for EZ-fill products in Europe and the US.

• Q1 2026 saw double-digit growth in the BDS segment (16%) and overall company growth of around 10%, with strong tailwinds from the biologics and GLP-1 markets.

• The company targets 30% EBITDA within 12-24 months, up from 25%, leveraging high-value product growth and operational excellence.

• Fishers plant is at 60% space occupancy, with a multi-year ramp-up expected to reach full capacity and revenue alignment.

Product and market trends

• The shift from bulk to ready-to-fill cartridges is accelerating, driven by customer demand, regulatory requirements (Annex 1), and cost efficiency.

• Ready-to-fill cartridges command up to 10x the price of bulk cartridges, with gross margins ranging from 40% to 70% depending on volume and complexity.

• The company is installing high-speed lines for cartridges in Latina, with a five- to six-year program to convert major clients to ready-to-fill platforms.

• The trend mirrors the earlier shift in syringes, where 98% of the market is now ready-to-fill.

• Biosimilar GLP-1 launches are adopting both syringe and cartridge formats, with the company actively validating products for originators and biosimilars globally.